Investment analysts at Nomura cut their price target on shares ofCelgene (NASDAQ:CELG) from $252.00 to $126.00 in a note issued to investors on Monday.Celgene Corporation (NASDAQ:CELG) net profit margin is 19.90% and weekly performance is 4.12%. On last trading day company shares ended up $90.19. Analysts mean target price for the company is $95.94. Celgene Corporation (NASDAQ:CELG) distance from 50-day simple moving average is 15.47%.
Shares of Questcor Pharmaceuticals (NASDAQ:QCOR) have earned an average rating of “Hold” from the twelve analysts that are currently covering the company. Seven analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company.Questcor Pharmaceuticals Inc (NASDAQ:QCOR) shares advanced 2.76% in last trading session and ended the day on $95.00. QCOR Gross Margin is 91.10% and its return on assets is 46.90%. Questcor Pharmaceuticals Inc (NASDAQ:QCOR) quarterly performance is 32.57%.
Portola Pharmaceuticals (NASDAQ:PTLA) CEO William Lis sold 30,000 shares of the stock in a transaction that occurred on Thursday, July 3rd. The shares were sold at an average price of $30.41, for a total value of $912,300.00. The sale was disclosed in a document filed with the Securities & Exchange Commission. Portola Pharmaceuticals Inc (NASDAQ:PTLA) shares moved down -0.91% in last trading session and was closed at $30.61, while trading in range of $30.14-$31.48. Portola Pharmaceuticals Inc (NASDAQ:PTLA) year to date performance is 18.87%.
On June 24, 2014 Ardelyx, Inc. (Nasdaq: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, GI and metabolic diseases, announced the closing of its initial public offering of 4,928,900 shares of common stock at an initial public offering price of $14.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 642,900 additional shares of common stock. All of the shares of common stock were offered by Ardelyx. The Company’s shares began trading on The NASDAQ Global Market under the ticker symbol “ARDX” on June 19, 2014. Ardelyx estimates net proceeds from the offering to be approximately $60.8 million, after deducting underwriting discounts and commissions and estimated offering expenses. Ardelyx Inc (NASDAQ:ARDX) ended the last trading day at $20.44. Company weekly volatility is calculated as 6.58% and price to cash ratio as 11.01. Ardelyx Inc (NASDAQ:ARDX) showed a positive weekly performance of 29.94%.